Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Intravenous immunoglobulin and plasma exchange
3 evidence topics · 3 sources
Short-term and maintenance use: international consensus guidance
“PLEX and IVIg are appropriately used as short-term treatments in patients with MG with life-threatening signs such as respiratory insufficiency or dysphagia; in preparation for surgery in patients with significant bulbar dysfunction; when a rapid response to treatment is needed; when other treatments are insufficiently effective; and prior to beginning corticosteroids if deemed necessary to prevent or minimize exacerbations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IVIg and PLEX are probably equally effective in the treatment of severe generalized MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of IVIg as maintenance therapy can be considered for patients with refractory MG or for those in whom IS agents are relatively contraindicated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PLEX and IVIg are the mainstay of management in myasthenic crisis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Crisis treatment and maintenance immunoglobulin: Nordic guidance
“Plasma exchange and intravenous immunoglobulin are the primary treatments recommended for crisis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Immunoglobulins, given intravenously or subcutaneously, are rarely used as maintenance therapy. A recent study found no steroid‐sparing effect of intravenous immunoglobulin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of immunoglobulin in generalized myasthenia gravis
“We included 12 RCTs (11 with usable data; 515 participants) conducted between 1997 and 2025 in Europe, North America, and Asia. All studies assessed IVIg; none assessed SCIg. Comparators included PLEX (six trials), placebo (five trials), and corticosteroids (one trial).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We found low‐certainty evidence that IVIg may improve symptoms and functional capacity in the medium term in people with MG, compared to placebo, though the effects did not reach commonly used thresholds for clinical significance and were based on sensitivity analyses. Based on moderate‐certainty evidence, IVIg probably also increases the incidence of headache. Based on very low to low‐certainty evidence, IVIg may be less beneficial than PLEX for short‐term improvement in symptoms and may prolong hospital stay, though we found no differences in adverse events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote